Skip to main navigation Skip to search Skip to main content

MRP1 and its role in anticancer drug resistance

Jamie F Lu, Deep Pokharel, Mary Bebawy

Research output: Contribution to journalArticlepeer-review

138 Citations (Scopus)

Abstract

The phenomenon of multidrug resistance (MDR) in cancer is associated with the overexpression of the ATP-binding cassette (ABC) transporter proteins, including multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein. MRP1 plays an active role in protecting cells by its ability to efflux a vast array of drugs to sub-lethal levels. There has been much effort in elucidating the mechanisms of action, structure and substrates and substrate binding sites of MRP1 in the last decade. In this review, we detail our current understanding of MRP1, its clinical relevance and highlight the current environment in the search for MRP1 inhibitors. We also look at the capacity for the rapid intercellular transfer of MRP1 phenotype from spontaneously shed membrane vesicles known as microparticles and discuss the clinical and therapeutic significance of this in the context of cancer MDR.

Original languageEnglish
Pages (from-to)406-419
JournalDrug Metabolism Reviews
Volume47
Issue number4
DOIs
Publication statusPublished - 31 Oct 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'MRP1 and its role in anticancer drug resistance'. Together they form a unique fingerprint.

Cite this